Efficacy of the regimen using twice-daily β-interferon followed by the standard of care for chronic hepatitis C genotype 1b with high viral load [0.03%]
高病毒载量基因1b型慢性丙型肝炎患者采用每日两次聚乙二醇干扰素进行治疗的疗效研究
Toru Ishikawa,Tomoyuki Kubota,Hiroyuki Abe et al.
Toru Ishikawa et al.
Aim: In patients with refractory genotype 1b chronic hepatitis C with high viral loads, we retrospectively compared the efficacy of standard of care treatment (SOC: combined PEG-IFN-α-2b/ribavirin for 48 weeks) and a re...
Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression? [0.03%]
乙型肝炎病毒和丙型肝炎病毒合并感染通过协同调节生脂基因的表达增加肝细胞癌的发生吗？
Qi Wu,Qiang Liu
Qi Wu
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections cause a wide range of liver diseases including hepatocellular carcinoma (HCC). Because of the similar modes of transmission, HBV HCV co-infections are found in approximately 7-2...
Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma [0.03%]
非酒精性脂肪肝炎向肝细胞癌发展的临床及病理过程
Kohichiroh Yasui,Etsuko Hashimoto,Katsutoshi Tokushige et al.
Kohichiroh Yasui et al.
Aim: Non-alcoholic steatohepatitis (NASH) can progress to hepatocellular carcinoma (HCC). We aimed to examine the clinical and pathological course of how NASH progresses to HCC. ...
Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib [0.03%]
索拉非尼治疗的晚期肝细胞癌患者的皮肤毒性和生存率
Taiga Otsuka,Yuichiro Eguchi,Seiji Kawazoe et al.
Taiga Otsuka et al.
Aim: Sorafenib is the first small molecule with significant clinical activity for advanced hepatocellular carcinoma (HCC). However, intolerable adverse events are sometimes observed. On the other hand, it has been report...
Splenic artery ligation: A protection against hepatic ischemia/reperfusion injury in partially hepatectomized rats [0.03%]
脾动脉结扎可保护部分肝切除大鼠再灌注时的肝脏损伤
Takumi Irie,Koji Ito,Hisashi Ozasa et al.
Takumi Irie et al.
Aim: In liver resection, the temporary occlusion of the hepatoduodenal ligament (Pringle maneuver) is often used. However, the maneuver causes ischemia/reperfusion (I/R) injury in the remnant liver. Heme oxygenase (HO)-1...
Mami Kanamoto,Mitsuo Shimada,Tohru Utsunomiya et al.
Mami Kanamoto et al.
Aim: Current medical transplantation methods focus on solutions for major problems such as the shortage of donors. To overcome these issues, expanding organ preservation time has become a major concern. A new refrigerati...
Diabetes, hepatitis virus infection and hepatocellular carcinoma: A case-control study in hepatitis endemic area [0.03%]
糖尿病、肝炎病毒感染及肝癌病例对照研究——兼论肝癌的病因学说
Wei-Hsu Ko,Sherry Yueh-Hsia Chiu,Kuo-Ching Yang et al.
Wei-Hsu Ko et al.
Aim: In spite of numerous studies on the association between diabetes mellitus (DM) and hepatocellular carcinoma (HCC), the results are inconsistent and whether and how the effect of DM on the risk for HCC is modified or...
Pulmonary embolism and deep venous thrombosis in hospitalized patients with liver cirrhosis [0.03%]
肝硬化住院患者的肺栓塞和深静脉血栓形成
Shun Kohsaka,Toshiyuki Nagai,Makito Yaegashi et al.
Shun Kohsaka et al.
Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C [0.03%]
慢性丙型肝炎常规治疗期间出现抗线粒体抗体-M2阳性自身免疫性肝炎
Fabio Salvatore Macaluso,Nicola Alessi,Daniela Cabibi
Fabio Salvatore Macaluso
The current standard of care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated-interferon (PEG-IFN) with ribavirin (RBV), may activate underlying autoimmune conditions. Particularly, interferon (IFN) has been known to induc...